The Food and Drug Administration approved a monoclonal antibody to protect infants and young children from severe illness caused by RSV on Monday, a potential game-changer for a disease that is the No ...

In a recent study published in Vaccines, researchers evaluated the impact of monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on maternal-fetal health.

Respiratory syncytial virus (RSV) is a common respiratory virus which usually causes mild, cold-like symptoms during the ...

This fall, for the first time many babies in the U.S. will be able to get a shot to fend off RSV, a respiratory virus that can cause serious lung disease in infants and young children. The Food and ...

In a fall in which new tools to fight old diseases — updated Covid-19 vaccines, new products to protect older adults and babies from RSV — have been introduced with fanfare but rolled out in a ...

Last winter’s respiratory syncytial virus, or RSV, season wasn’t as brutal for U.S. babies. A new study suggests two preventive tools — a maternal vaccine and a monoclonal antibody for infants — may ...

A federal advisory committee has voted unanimously to recommend a new drug to prevent severe respiratory syncytial virus, or RSV, in babies and certain toddlers ahead of the cold season starting in ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

Chris Blyth receives funding from the Australian Department of Health and Aged Care, National Health and Medical Research Council and the Perron Trust for RSV-related research. He has previously been ...

Monoclonal antibodies have been around for decades. Antibody medicines like the one that earned President Donald Trump's praise after treatment earlier this month are not just for COVID-19. For the ...

Is it possible to improve the antibodies that the body produces to fight SARS-CoV2? In a study led by researchers from Lund University in Sweden, this was investigated by redesigning antibodies and ...